OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
January 19, 2021
The process of distributing millions of doses of new vaccines across the nation has been much less effective than anticipated.
January 14, 2021
Administration officials continue to rush through new rules and decisions that appear to challenge the independence and effective operations of FDA.
January 12, 2021
Biden administration faces key decisions on drug testing and access amid vaccine distribution challenges.
January 07, 2021
CDER's process for vetting and authorizing important new therapies remained strong and productive last year, despite the need to deal with COVID-19 related approvals and policies.
Applications put on hold as agency limits alternative oversight methods.
January 05, 2021
Examining the current biosimilar market.
December 31, 2020
President Trump finally signs the critical year-end COVID-19 package, appropriating $2.3 trillion to finance the federal government through September 2021 and providing critical support for individuals and entities suffering from the economic crisis wrought by the pandemic.
December 28, 2020
Jill Wechsler reports on FDA's newly published strategies supporting broader eligibility criteria for Phase III studies.
December 15, 2020
Outlining the steps to a payment approach for Medicare Part D drugs that provides savings for patients.
December 11, 2020
2020 has proven to be a year like no other for pharma. Here is a quick look back at some of the trends 2020 created for the industry.